Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

Abstract

Natural products, originating from diverse biological sources, serve as a critical reservoir of bioactive compounds for cancer intervention across prevention, treatment, and supportive care. Their mechanisms extend beyond direct cytotoxicity to include modulation of tumor metabolism—such as glucose, lipid, and glutamine pathways—and the tumor microenvironment (TME), highlighting their multifaceted role in oncology. However, a systematic synthesis of how natural products concurrently target metabolic reprogramming and immune–stromal components across different clinical phases remains lacking. This review delineates the therapeutic applications of natural products—such as flavonoids, alkaloids, and terpenoids—across the clinical continuum, including perioperative support, concurrent chemoradiotherapy, maintenance therapy, and metastasis suppression. We detail their actions in disrupting core metabolic pathways and elucidate their influence on TME components like cancer-associated fibroblasts, extracellular matrix, and immune cells including tumor-associated macrophages and T lymphocytes. Furthermore, we discuss innovative delivery strategies—including nanocarriers and codelivery systems—that enhance bioavailability and enable synergistic combination with chemotherapy or immunotherapy. By integrating mechanistic insights with clinical translation strategies, this work provides a comprehensive framework for employing natural products in biomarker-driven, precision oncology regimens, supporting their evolving role in multimodal cancer care.

Keywords

cancer metabolic reprogramming / immune modulation / natural products / precision medicine / tumor microenvironment

References

[1] Y. Zhu, Z. J. Ouyang, H. J. Du, et al., “New Opportunities and Challenges of Natural Products Research: When Target Identification Meets Single-cell Multiomics,” Acta Pharmaceutica Sinica B 12, no. 11 (2022): 4011–4039.

[2] S. H. Lee, J. K. Ryu, K. Y. Lee, et al., “Enhanced Anti-tumor Effect of Combination Therapy With Gemcitabine and Apigenin in Pancreatic Cancer,” Cancer Letters 259, no. 1 (2008): 39–49.

[3] E. A. Mohamad, M. R. El-Garhy, and M. M. Rageh, “Improving Cisplatin Chemotherapy in Vivo by Niosomal Propolis and Chrysin as Nanoadjuvants,” Medical Oncology 42, no. 12 (2025): 539.

[4] H. Shulan, N. Peng, L. Likun, et al., “Effectiveness of Yiqi Chupi Powder for Alleviating Cancer-related Fatigue in Patients Following Colorectal Cancer Surgery: A Randomized Controlled Trial,” Journal of Traditional Chinese Medicine 45, no. 5 (2025): 1119–1126.

[5] F. Yang, Z. Li, H. Zhang, et al., “Natural Product Erianin: Mitigating FOLFOX Toxicity and Enhancing Against Colorectal Cancer,” Front Chem 13 (2025): 1650197.

[6] J. Cai, Z. R. Xuan, Y. P. Wei, H. B. Yang, and H. Wang, “[Effects of perioperative administration of Rhubarb on acute inflammatory response in patients With gastric cancer],” Zhong Xi Yi Jie He Xue Bao = Journal of Chinese Integrative Medicine 3, no. 3 (2005): 195–198.

[7] Y. Zheng, N. Feng, C. L. Li, and Z. Q. Li, “Natural Products Target Programmed Cell Death Signaling Mechanisms to Treat Colorectal Cancer,” Frontiers In Pharmacology 16 (2025): 26.

[8] C. Yu, C. Jia, G. Chen, et al., “Yiai Fuzheng Decoction Inhibits Triple-negative Breast Cancer by Remodeling the Immune Microenvironment,” Frontiers In Immunology 16 (2025): 1615631.

[9] M. Demeule, M. Brossard, S. Turcotte, et al., “Diallyl Disulfide, a Chemopreventive Agent in Garlic, Induces Multidrug Resistance-associated Protein 2 Expression,” Biochemical and Biophysical Research Communications 324, no. 2 (2004): 937–945.

[10] A. B. P. van Kuilenburg, R. Meinsma, and A. H. van Gennip, “Pyrimidine Degradation Defects and Severe 5-fluorouracil Toxicity,” Nucleosides Nucleotides & Nucleic Acids 23, no. 8-9 (2004): 1371–1375.

[11] M. M. Monteiro, B. B. Silveira, L. Di Carvalho Melo, et al., “Chitosan-Based Systems for Curcumin Delivery: Evidence for Therapeutic Applications,” Journal of Biochemical and Molecular Toxicology 39, no. 10 (2025): e70515.

[12] K. Subban and F. Kempken, “Insights Into Taxol® Biosynthesis by Endophytic Fungi,” Applied Microbiology And Biotechnology 107, no. 20 (2023): 6151–6162.

[13] P. Y. Yao, S. Liang, Z. Y. Liu, and C. P. Xu, “A Review of Natural Products Targeting Tumor Immune Microenvironments for the Treatment of Lung Cancer,” Frontiers In Immunology 15 (2024): 26.

[14] C. Gerhäuser, “Cancer Cell Metabolism, Epigenetics and the Potential Influence of Dietary Components—A Perspective,” Biomedical Research-India 23 (2012): 69–89.

[15] J. C. Wu, H. Ji, T. T. Li, et al., “Targeting the Prostate Tumor Microenvironment by Plant-derived Natural Products,” Cellular Signalling 115 (2024): 15.

[16] Y. Hu, J. Z. Song, A. J. Feng, et al., “Recent Advances in Nanotechnology-Based Targeted Delivery Systems of Active Constituents in Natural Medicines for Cancer Treatment,” Molecules (Basel, Switzerland) 28, no. 23 (2023): 33.

[17] Z. Li, T. T. Zhao, J. X. Li, et al., “Nanomedicine Based on Natural Products: Improving Clinical Application Potential,” Journal Of Nanomaterials 2022 (2022): 11.

[18] S. Dutta, S. Mahalanobish, S. Saha, S. Ghosh, and P. C. Sil, “Natural Products: An Upcoming Therapeutic Approach to Cancer,” Food And Chemical Toxicology 128 (2019): 240–255.

[19] A. W. Shi, L. Liu, S. Li, and B. Qi, “Natural Products Targeting the MAPK-signaling Pathway in Cancer: Overview,” Journal Of Cancer Research And Clinical Oncology 150, no. 1 (2024): 20.

[20] D. Zhou, Z. S. Bai, and T. T. Guo, “Dietary Flavonoids and human Top-ranked Diseases: The Perspective of in Vivo Bioactivity and Bioavailability,” Trends In Food Science & Technology 120 (2022): 374–386.

[21] A. A. Khalil, A. Rauf, F. A. Alhumaydhi, et al., “Recent Developments and Anticancer Therapeutics of Paclitaxel: An Update,” Current Pharmaceutical Design 28, no. 41 (2022): 3363–3373.

[22] W. X. Fan, L. H. Fan, Z. Y. Wang, et al., “Rare Ginsenosides: A Unique Perspective of Ginseng Research,” Journal Of Advanced Research 66 (2024): 303–328.

[23] D. Shah, N. Challagundla, V. Dave, et al., “Berberine Mediates Tumor Cell Death by Skewing Tumor-associated Immunosuppressive Macrophages to Inflammatory Macrophages,” Phytomedicine 99 (2022): 12.

[24] G. W. Qin and R. S. Xu, “Recent Advances on Bioactive Natural Products From Chinese Medicinal Plants,” Medicinal Research Reviews 18, no. 6 (1998): 375–382.

[25] B. Cong, “Perspectives in Food & Amp; Medicine Homology,” Food & Medicine Homology 1, no. 1 (2024): 9420018.

[26] H. Qamar, S. Rehman, and D. K. Chauhan, “Current Status and Future Perspective for Research on Medicinal Plants With Anticancerous Activity and Minimum Cytotoxic Value,” Current Drug Targets 20, no. 12 (2019): 1227–1243.

[27] J. Li, S. Han, Y. Zhu, B. Dong, and A. Halorotetin, “A Novel Terpenoid Compound Isolated From Ascidian Halocynthia rotetzi Exhibits the Inhibition Activity on Tumor Cell Proliferation,” Marine Drugs 21, no. 1 (2023): 51.

[28] B. Mubeen, A. Hasnain, S. A. H. Naqvi, et al., “Phytochemicals as Multi-Target Therapeutic Agents for Oxidative Stress-Driven Pathologies: Mechanisms, Synergies, and Clinical Prospects,” Phyton-International Journal Of Experimental Botany 94, no. 7 (2025): 1941–1971.

[29] Y. Wang, X. Huang, J. Han, W. Zheng, and W. Ma, “Extract of Perilla Frutescens Inhibits Tumor Proliferation of HCC via PI3K/AKT Signal Pathway,” Afr J Tradit Complement Altern Med 10, no. 2 (2013): 251–257.

[30] Y. Zhou, Y. Li, T. Zhou, et al., “Dietary Natural Products for Prevention and Treatment of Liver Cancer,” Nutrients 8, no. 3 (2016): 156.

[31] J. A. Ross and C. M. Kasum, “Dietary Flavonoids: Bioavailability, Metabolic Effects, and Safety,” Annual Review Of Nutrition 22 (2002): 19–34.

[32] M. Li, M. Q. Qian, Q. Jiang, et al., “Evidence of Flavonoids on Disease Prevention,” Antioxidants 12, no. 2 (2023): 19.

[33] T. Y. Wang, Q. Li, and K. S. Bi, “Bioactive Flavonoids in Medicinal Plants: Structure, Activity and Biological Fate,” Asian Journal Of Pharmaceutical Sciences 13, no. 1 (2018): 12–23.

[34] X. Li, X. He, B. Lin, et al., “Quercetin Limits Tumor Immune Escape Through PDK1/CD47 Axis in Melanoma,” American Journal Of Chinese Medicine 52, no. 02 (2024): 541–563.

[35] I. Ahmad, S. Fakhri, H. Khan, et al., “Targeting Cell Cycle by β-carboline Alkaloids in Vitro: Novel Therapeutic Prospects for the Treatment of Cancer,” Chemico-Biological Interactions 330 (2020): 9.

[36] C. V. Rao, C. D. Kurkjian, and H. Y. Yamada, “Mitosis-Targeting Natural Products for Cancer Prevention and Therapy,” Current Drug Targets 13, no. 14 (2012): 1820–1830.

[37] S. C. Leonard, H. Lee, D. F. Gaddy, et al., “Extended Topoisomerase 1 Inhibition Through Liposomal Irinotecan Results in Improved Efficacy Over topotecan and irinotecan in Models of Small-cell Lung Cancer,” Anti-Cancer Drugs 28, no. 10 (2017): 1086–1096.

[38] C. El-Baba, A. Baassiri, G. Kiriako, et al., “Terpenoids' anti-cancer Effects: Focus on Autophagy,” Apoptosis 26, no. 9-10 (2021): 491–511.

[39] M. Asensi, A. Ortega, S. Mena, F. Feddi, and J. M. Estrela, “Natural Polyphenols in Cancer Therapy,” Critical Reviews In Clinical Laboratory Sciences 48, no. 5-6 (2011): 197–216.

[40] A. Brockmueller, S. Sameri, A. Liskova, et al., “Resveratrol's Anti-Cancer Effects Through the Modulation of Tumor Glucose Metabolism,” Cancers 13, no. 2 (2021): 35.

[41] K. W. Luo, W. Chen, W. Y. Lung, et al., “EGCG Inhibited Bladder Cancer SW780 Cell Proliferation and Migration both in Vitro and in Vivo via Down-regulation of NF-κB and MMP-9,” Journal Of Nutritional Biochemistry 41 (2017): 56–64.

[42] V. M. Shah, S. Rizvi, A. Smith, et al., “Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment,” Pharmaceutics 15, no. 12 (2023): 26.

[43] Z. T. Xu, X. U. Chen, Z. F. Zhong, L. D. Chen, and Y. T. Wang, “Ganoderma Lucidum Polysaccharides: Immunomodulation and Potential Anti-Tumor Activities,” American Journal Of Chinese Medicine 39, no. 1 (2011): 15–27.

[44] G. Maskarinec, D. Ju, Y. Morimoto, A. A. Franke, and F. Z. Stanczyk, “Soy Food Intake and Biomarkers of Breast Cancer Risk: Possible Difference in Asian Women?,” Nutrition And Cancer 69, no. 1 (2017): 146–153.

[45] M. E. Vaccari, V. Cavalloro, M. Bedeschi, et al., “Preparation of a Micronutrient-Enriched Apricot Kernel Oil and Assessment of in Vitro Chemopreventive Properties,” International Journal Of Molecular Sciences 26, no. 18 (2025).

[46] W. Rzeska, M. Chojnacki, A. Adamiak-Godlewska, A. Semczuk, and M. K. Lemieszek, “First Look at Chemopreventive Properties of Chlorella Pyrenoidosa Water Extract in Human Endometrial Adenocarcinoma Cells-Preliminary in Vitro Study,” International Journal Of Molecular Sciences 26, no. 18 (2025): 9142.

[47] M. Ławiński, K. Zadka, N. Ksepka, et al., “Does Resveratrol Impact Oxidative Stress Markers in Patients With Head and Neck Cancer Receiving Home Enteral Nutrition?,” Nutrients 17, no. 3 (2025): 504.

[48] C. Cheon, H. Kim, S. Y. Kang, et al., “Safety Evaluation of SH003 and Docetaxel Combination in Patients with Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial,” Integrative Cancer Therapies 24 (2025): 15347354251363892.

[49] D. R. Ferry, A. Smith, J. Malkhandi, et al., “Phase I Clinical Trial of the Flavonoid Quercetin: Pharmacokinetics and Evidence for in Vivo Tyrosine Kinase Inhibition,” Clinical Cancer Research 2, no. 4 (1996): 659–668.

[50] X. Yin, W. Zhu, X. Tang, et al., “Phase I/II Clinical Trial of Efficacy and Safety of EGCG Oxygen Nebulization Inhalation in the Treatment of COVID-19 Pneumonia Patients With Cancer,” BMC cancer 24, no. 1 (2024): 486.

[51] T. Ge, H. Li, P. Xiang, et al., “Tanshinone IIA Induces Ferroptosis in Colorectal Cancer Cells Through the Suppression of SLC7A11 Expression via the PI3K/AKT/mTOR Pathway,” European Journal Of Medical Research 30, no. 1 (2025): 576.

[52] K. Iwasaki, E. Barroga, Y. Takano, et al., “Effects of Rikkunshito on Postgastrectomy Weight Loss and Nutritional Status in Gastric Cancer Patients: A Retrospective Observational Study,” Medicine 104, no. 33 (2025): e43950.

[53] M. Wang, S. J. Yan, H. T. Zhang, et al., “Ginsenoside Rh2 Enhances the Antitumor Immunological Response of a Melanoma Mice Model,” Oncology Letters 13, no. 2 (2017): 681–685.

[54] W. Xu, Y. Li, L. Liu, et al., “Icaritin-curcumol Activates CD8(+) T Cells Through Regulation of Gut Microbiota and the DNMT1/IGFBP2 Axis to Suppress the Development of Prostate Cancer,” Journal Of Experimental & Clinical Cancer Research 43, no. 1 (2024): 149.

[55] W. Gao, S. Xu, B. Kang, et al., “Sodium Hyaluronate-modified Fe(III)-shikonin Self-assembly Nanoparticle for Effective Tumor Therapy and Reduced Tumor Metastasis,” Carbohydrate Polymers 367 (2025): 123939.

[56] Y. X. Chen, Q. Y. Gao, T. H. Zou, et al., “Berberine versus Placebo for the Prevention of Recurrence of Colorectal Adenoma: A Multicentre, Double-blinded, Randomised Controlled Study,” Lancet Gastroenterol Hepatol 5, no. 3 (2020): 267–275.

[57] W. U. Ruixin, F. Qingliang, G. Sisi, et al., “A Pilot Study of Precision Treatment for Patients With Lung Cancer Pain by Longteng Tongluo Recipe Using Serum Genomics,” Journal Of Traditional Chinese Medicine 44, no. 5 (2024): 1006–1016.

[58] O. L. Elvir-Lazo, P. F. White, H. C. Eng, et al., “Impact of Chronic Medications in the Perioperative Period: Mechanisms of Action and Adverse Drug Effects (Part I),” Postgraduate Medicine 133, no. 8 (2021): 939–952.

[59] Y. K. Liu, J. He, M. Li, K. B. Ren, and Z. H. Zhao, “Inflammation-Driven Nanohitchhiker Enhances Postoperative Immunotherapy by Alleviating Prostaglandin E2-Mediated Immunosuppression,” Acs Applied Materials & Interfaces 16, no. 6 (2024): 6879–6893.

[60] S. Takiguchi, Y. Hiura, T. Takahashi, et al., “Effect of Rikkunshito, a Japanese Herbal Medicine, on Gastrointestinal Symptoms and Ghrelin Levels in Gastric Cancer Patients After Gastrectomy,” Gastric Cancer 16, no. 2 (2013): 167–174.

[61] R. F. Ozols, “Challenges for Chemotherapy in Ovarian Cancer,” Annals Of Oncology 17 (2006): V181–V187.

[62] J. Jin, S. Ren, Q. Shi, et al., “Shengbai Oral Solution for Chemotherapy-induced Neutropenia and Symptom Management in Non-small Cell Lung Cancer: A Multicenter, Randomized, Open-label Trial,” Phytomedicine 148 (2025): 157502.

[63] J. R. Hu, Q. Ji, W. W. He, et al., “Efficacy of Modified Peanut Skin Decoction for Lung Cancer Myelosuppression,” Journal Of Visualized Experiments: JoVE no. 223 (2025).

[64] J. Zhang, L. Zhang, C. Wang, et al., “The Fritillaria Alkaloid Peiminine Acts as a Chemosensitizer to Potentiate Oxaliplatin Efficacy Against Gastric Cancer,” Pathology, Research and Practice 275 (2025): 156208.

[65] Q. Liu, Q. Zhou, X. Yang, et al., “Tanshinone IIA Is Synergistic With the PARP Inhibitor olaparib in Inducing BRCAs-proficient and -deficient Triple-negative Breast Cancer Cell Apoptosis,” Medical Oncology 42, no. 9 (2025): 419.

[66] J. Yao, J. Liu, Y. He, et al., “Systems Pharmacology Reveals the Mechanism of Astragaloside IV in Improving Immune Activity on Cyclophosphamide-induced Immunosuppressed Mice,” Journal Of Ethnopharmacology 313 (2023): 116533.

[67] Y. Zhong, Q. Xiao, J. Huang, et al., “Ginsenoside Rg1 Alleviates Ulcerative Colitis in Obese Mice by Regulating the Gut Microbiota-Lipid Metabolism-Th1/Th2/Th17 Cells Axis,” Journal Of Agricultural And Food Chemistry 71, no. 50 (2023): 20073–20091.

[68] M. Y. Huang, Y. C. Chen, W. Y. Lyu, et al., “Ginsenoside Rh2 Augmented Anti-PD-L1 Immunotherapy by Reinvigorating CD8(+) T Cells via Increasing Intratumoral CXCL10,” Pharmacological Research 198 (2023): 106988.

[69] X. Lu, A. Wang, D. Chen, et al., “Gegen Qinlian Tablets Attenuate Immune-related Adverse Events in NSCLC Patients: A Multi-center Randomized Controlled Trial in China,” Phytomedicine 145 (2025): 156968.

[70] J. Y. Shi, Y. J. Wang, Q. W. Bao, et al., “Polygonatum Cyrtonema Hua Polysaccharide Alleviates Ulcerative Colitis via Gut Microbiota-independent Modulation of Inflammatory Immune Response,” Carbohydrate Polymers 356 (2025): 19.

[71] M. Dong, Z. Meng, K. Kuerban, et al., “Diosgenin Promotes Antitumor Immunity and PD-1 Antibody Efficacy Against Melanoma by Regulating Intestinal Microbiota,” Cell Death & Disease 9, no. 10 (2018): 1039.

[72] B. Li, T. Xiang, M. Bindawa Isah, C. Chen, and X. Zhang, “In Vitro Simulated Saliva, Gastric, and Intestinal Digestion Followed by Faecal Fermentation Reveals a Potential Modulatory Activity of Epimedium on human Gut Microbiota,” Journal Of Pharmaceutical And Biomedical Analysis 245 (2024): 116151.

[73] H. Tazoe, Y. Otomo, I. Kaji, et al., “Roles of Short-chain Fatty Acids Receptors, GPR41 and GPR43 on Colonic Functions,” Journal Of Physiology And Pharmacology 59 (2008): 251–262. Suppl 2.

[74] M. G. Bae, J. Hwang-Bo, D. Y. Lee, Y. H. Lee, and I. S. Chung, “Effects of 6,8-Diprenylgenistein on VEGF-A-Induced Lymphangiogenesis and Lymph Node Metastasis in an Oral Cancer Sentinel Lymph Node Animal Model,” International Journal Of Molecular Sciences 22, no. 2 (2021).

[75] L. Avila-Carrasco, P. Majano, J. A. Sánchez-Toméro, et al., “Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition,” Frontiers In Pharmacology 10 (2019): 715.

[76] W. Liu, M. Hu, F. Cao, and S. Jin, “Polyphenols and Exercise in Autophagy Regulation: Potential Benefits for Cancer Management and Healthspan,” Frontiers in Nutrition 12 (2025): 1618813.

[77] C. Buhrmann, P. Shayan, A. Brockmueller, and M. Shakibaei, “Resveratrol Suppresses Cross-Talk Between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge Between in Vitro and in Vivo Tumor Microenvironment Study,” Molecules (Basel, Switzerland) 25, no. 18 (2020): 4292.

[78] Y. Hijikata, “Analgesic Treatment With Kampo Prescription,” Expert Review Of Neurotherapeutics 6, no. 5 (2006): 795–802.

[79] F. Inferrera, N. Tranchida, R. Fusco, et al., “Neuronutritional Enhancement of Antioxidant Defense System Through Nrf2/HO1/NQO1 Axis in Fibromyalgia,” Neurochemistry International 190 (2025): 106057.

[80] Z. Y. Su, Z. Z. Yang, Y. Q. Xu, Y. B. Chen, and Q. Yu, “Apoptosis, Autophagy, Necroptosis, and Cancer Metastasis,” Molecular Cancer 14 (2015): 14.

[81] J. D. Martin, G. Seano, and R. K. Jain, “Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges,” Annual Review Of Physiology 81 (2019): 505–534.

[82] F. Cao, H. L. Zhang, C. Guo, X. L. Xu, and Q. Yuan, “Targeting Oxidative Stress With Natural Products: A Novel Strategy for Esophageal Cancer Therapy,” World Journal Of Gastrointestinal Oncology 16, no. 2 (2024): 14.

[83] A. R. Guerra, M. F. Duarte, and I. F. Duarte, “Targeting Tumor Metabolism With Plant-Derived Natural Products: Emerging Trends in Cancer Therapy,” Journal Of Agricultural And Food Chemistry 66, no. 41 (2018): 10663–10685.

[84] C. M. Pfeffer and A. T. K. Singh, “Apoptosis: A Target for Anticancer Therapy,” International Journal Of Molecular Sciences 19, no. 2 (2018): 10.

[85] K. J. Campbell and S. W. G. Tait, “Targeting BCL-2 Regulated Apoptosis in Cancer,” Open Biology 8, no. 5 (2018): 11.

[86] B. Tummers and D. R. Green, “Caspase-8: Regulating Life and Death,” Immunological Reviews 277, no. 1 (2017): 76–89.

[87] S. N. Qian, Z. Wei, W. T. Yang, et al., “The Role of BCL-2 family Proteins in Regulating Apoptosis and Cancer Therapy,” Frontiers In Oncology 12 (2022): 16.

[88] B. K. Utpal, H. Bouenni, M. Zehravi, et al., “Exploring Natural Products as Apoptosis Modulators in Cancers: Insights Into Natural Product-based Therapeutic Strategies,” Naunyn-Schmiedebergs Archives Of Pharmacology 398, no. 7 (2025): 8189–8214.

[89] G. Moriasi, M. Ngugi, P. Mwitari, and G. Omwenga, “Promising Anti-cervical Cancer Efficacy and Phytochemical Analysis of Vitex doniana Sweet (Verbenaceae) Leaf Extracts: An in Vitro Investigation With Molecular Mechanisms of Action,” BMC Complement Med Ther 25, no. 1 (2025): 379.

[90] M. A. Ghareeb, B. Bakchiche, Y. Aouiffat, et al., “LC/ESI-MS/MS Phytochemical Profiling and Apoptotic Effect of Haloxylon Scoparium Leaf Extract on Hepatocellular Carcinoma,” Scientific Reports 15, no. 1 (2025): 37154.

[91] L. Liu, Y. Liu, S. Zhang, et al., “Celastrol Promotes Apoptosis of Breast Cancer MDA-MB-231 Cells by Targeting HSDL2,” Acupuncture And Herbal Medicine 4, no. 1 (2024): 92–101.

[92] G. Sahoo, D. Samal, P. Khandayataray, and M. K. Murthy, “A Review on Caspases: Key Regulators of Biological Activities and Apoptosis,” Molecular Neurobiology 60, no. 10 (2023): 5805–5837.

[93] M. Asadi, S. Taghizadeh, E. Kaviani, et al., “Caspase-3: Structure, Function, and Biotechnological Aspects,” Biotechnology And Applied Biochemistry 69, no. 4 (2022): 1633–1645.

[94] D. Shekarabi, S. Safi, and P. Mortazavi, “Evaluation of Apoptosis and Caspase-3 Activity in EL4 Cell Line Lymphoma Using Moringa Oleifera Plant Extract,” Archives of Razi Institute 80, no. 1 (2025): 37–50.

[95] A. M. Mousa, N. M. El-Sammad, A. H. Abdel-Halim, et al., “Lagerstroemia Speciosa (L.) Pers Leaf Extract Attenuates Lung Tumorigenesis via Alleviating Oxidative Stress,” Biomolecules 9, no. 12 (2019).

[96] B. Pucci, M. Kasten, and A. Giordano, “Cell Cycle and Apoptosis,” Neoplasia 2, no. 4 (2000): 291–299.

[97] M. Zhong, Y. Li, H. Wang, et al., “Integrated Network Pharmacology and Experimental Validation Reveal EGFR/p53/Bcl-2-mediated Anti-hepatocellular Carcinoma Effects of Zedoary Turmeric Oil,” Journal Of Ethnopharmacology 352 (2025): 120241.

[98] T. H. Wang, H. S. Wang, and Y. K. Soong, “Paclitaxel-induced Cell Death -: Where the Cell Cycle and Apoptosis Come Together,” Cancer 88, no. 11 (2000): 2619–2628.

[99] S. J. Choi, J. H. Kim, H. J. Kim, et al., “Triggering Mitotic Catastrophe by Podophyllotoxin Induces Apoptosis in Oral Squamous Cell Carcinoma,” Archives Of Oral Biology 179 (2025): 10.

[100] O. Prakash, R. Singh, N. Singh, et al., “Anticancer Potential of Naringenin, Biosynthesis, Molecular Target, and Structural Perspectives,” Mini - Reviews In Medicinal Chemistry 22, no. 5 (2022): 758–769.

[101] Y. Huang, Y. Zhou, Y. Fan, and D. Zhou, “Celastrol Inhibits the Growth of human Glioma Xenografts in Nude Mice Through Suppressing VEGFR Expression,” Cancer Letters 264, no. 1 (2008): 101–106.

[102] Z. Li, Q. Zhang, X. Zhang, et al., “Dihydroartemisinin Inhibits Melanoma Migration and Metastasis by Affecting Angiogenesis,” Phytotherapy Research 39, no. 4 (2025): 1679–1693.

[103] M. Najafi, B. Farhood, and K. Mortezaee, “Extracellular Matrix (ECM) Stiffness and Degradation as Cancer Drivers,” Journal Of Cellular Biochemistry 120, no. 3 (2019): 2782–2790.

[104] R. A. Reddy, M. S. Varshini, and R. S. Kumar, “Matrix Metalloproteinase-2 (MMP-2): As an Essential Factor in Cancer Progression,” Recent Patents On Anti-Cancer Drug Discovery 20, no. 1 (2025): 26–44.

[105] N. M. Abdel-Hamid and S. A. Abass, “Matrix Metalloproteinase Contribution in Management of Cancer Proliferation, Metastasis and Drug Targeting,” Molecular Biology Reports 48, no. 9 (2021): 6525–6538.

[106] X. Peng, Q. Zhang, Y. Zeng, et al., “Evodiamine Inhibits the Migration and Invasion of Nasopharyngeal Carcinoma Cells in Vitro via Repressing MMP-2 Expression,” Cancer Chemotheraphy And Pharmacology 76, no. 6 (2015): 1173–1184.

[107] T. Zhou, A. J. Zhang, G. Kuang, et al., “Baicalin Inhibits the Metastasis of Highly Aggressive Breast Cancer Cells by Reversing Epithelial-to-mesenchymal Transition by Targeting β-catenin Signaling,” Oncology Reports 38, no. 6 (2017): 3599–3607.

[108] X. F. Wang, Q. M. Zhou, J. Du, et al., “Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway,” Anti-Cancer Agents In Medicinal Chemistry 13, no. 6 (2013): 923–931.

[109] Ü. Yırtıcı, A. Ergene, Ş. Adem, et al., “Centaurea Mersinensis Phytochemical Composition and Multi-dimensional Bioactivity Properties Supported by Molecular Modeling,” Journal Of Biomolecular Structure & Dynamics 42, no. 5 (2024): 2341–2357.

[110] A. Korniluk, O. Koper, H. Kemona, and V. Dymicka-Piekarska, “From Inflammation to Cancer,” Irish Journal Of Medical Science 186, no. 1 (2017): 57–62.

[111] Y. Z. Wu, S. Antony, J. L. Meitzler, and J. H. Doroshow, “Molecular Mechanisms Underlying Chronic Inflammation-associated Cancers,” Cancer Letters 345, no. 2 (2014): 164–173.

[112] H. H. Rahman, D. Niemann, and S. H. Munson-McGee, “Association Between Asthma, Chronic Bronchitis, Emphysema, Chronic Obstructive Pulmonary Disease, and Lung Cancer in the US Population,” Environmental Science And Pollution Research 30, no. 8 (2023): 20147–20158.

[113] D. M. Ma, X. W. Dong, X. Han, et al., “Pancreatitis and Pancreatic Cancer Risk,” Technology In Cancer Research & Treatment 22 (2023): 8.

[114] R. Mansilla-Vivar, C. A. Serrano, C. Palma, et al., “High Helicobacter pylori Bacterial Load and Low Cytokine Expression Levels Are Associated With Nodular Gastropathy,” Digestive Diseases And Sciences 65, no. 2 (2020): 565–575.

[115] L. H. Jia, Y. L. Hu, G. H. Yang, and P. L. Li, “Puerarin Suppresses Cell Growth and Migration in HPV-positive Cervical Cancer Cells by Inhibiting the PI3K/mTOR Signaling Pathway,” Experimental And Therapeutic Medicine 18, no. 1 (2019): 543–549.

[116] Z. Wu, S. Kan, C. Li, and X. Lu, “Effect of puerarin on Apoptosis of human Hepatocellular Carcinoma Cells Under Oxidative Stress and Its Mechanisms,” J buon 24, no. 2 (2019): 628–633.

[117] X. Wang, J. Zhao, Y. Li, S. Gao, and L. Su, “Luteolin as a Multifaceted Immunomodulator: Insights Into Its Effects on Diverse Immune Cell Populations and Therapeutic Implications,” Frontiers In Immunology 16 (2025): 1621367.

[118] M. Panji, V. Behmard, Z. Zare, et al., “Suppressing Effects of Green Tea Extract and Epigallocatechin-3-gallate (EGCG) on TGF-β- induced Epithelial-to-mesenchymal Transition via ROS/Smad Signaling in human Cervical Cancer Cells,” Gene 794 (2021): 145774.

[119] S. Tabassum, J. S. Ali, R. F. Saeed, et al., “Bioactivity-Directed Isolation of Anticancer Constituents From Underexplored Folklore: Rhus punjabensis Stewart,” Molecules (Basel, Switzerland) 30, no. 22 (2025).

[120] K. Y. Zhu, Y. Cai, L. Lan, and N. Luo, “Tumor Metabolic Reprogramming and Ferroptosis: The Impact of Glucose, Protein, and Lipid Metabolism,” International Journal Of Molecular Sciences 25, no. 24 (2024): 23.

[121] P. Vaupel, H. Schmidberger, and A. Mayer, “The Warburg Effect: Essential Part of Metabolic Reprogramming and central Contributor to Cancer Progression,” International Journal Of Radiation Biology 95, no. 7 (2019): 912–919.

[122] X. H. Guo, S. S. Jiang, L. L. Zhang, et al., “Berberine Exerts Its Antineoplastic Effects by Reversing the Warburg Effect via Downregulation of the Akt/mTOR/GLUT1 Signaling Pathway,” Oncology Reports 46, no. 6 (2021): 253.

[123] L. Jia, S. Huang, X. Yin, et al., “Quercetin Suppresses the Mobility of Breast Cancer by Suppressing Glycolysis Through Akt-mTOR Pathway Mediated Autophagy Induction,” Life Sciences 208 (2018): 123–130.

[124] Y. Zhao, W. Lai, Y. Xu, et al., “Exogenous and Endogenous Therapeutic Effects of Combination Sodium Ferulate and Bone Marrow Stromal Cells (BMSCs) Treatment Enhance Neurogenesis After Rat Focal Cerebral Ischemia,” Metabolic Brain Disease 28, no. 4 (2013): 655–666.

[125] T. Zhan, M. Digel, E. M. Küch, W. Stremmel, and J. Füllekrug, “Silybin and Dehydrosilybin Decrease Glucose Uptake by Inhibiting GLUT Proteins,” Journal Of Cellular Biochemistry 112, no. 3 (2011): 849–859.

[126] Y. J. Tan, A. Ali, S. Y. Tee, et al., “Galloyl Esters of Trans-stilbenes Are Inhibitors of FASN With Anticancer Activity on Non-small Cell Lung Cancer Cells,” European Journal Of Medicinal Chemistry 182 (2019): 111597.

[127] M. C. Nocito, P. Avena, L. Zavaglia, et al., “Adrenocortical Carcinoma (ACC) Cells Rewire Their Metabolism to Overcome Curcumin Antitumoral Effects Opening a Window of Opportunity to Improve Treatment,” Cancers (Basel) 15, no. 4 (2023): 1050.

[128] M. Shi, Y. Mobet, and H. Shen, “Quercetin Attenuates Acute Kidney Injury Caused by Cisplatin by Inhibiting Ferroptosis and Cuproptosis,” Cell Biochemistry AOnd Biophysics 82, no. 3 (2024): 2687–2699.

[129] A. Shahzad, W. J. Liu, Y. J. Sun, et al., “Flavonoids as Modulators of Metabolic Reprogramming in Renal Cell Carcinoma (Review),” Oncology Reports 52, no. 6 (2024): 17.

[130] M. Samec, A. Mazurakova, V. Lucansky, et al., “Flavonoids Attenuate Cancer Metabolism by Modulating Lipid Metabolism, Amino Acids, Ketone Bodies and Redox state Mediated by Nrf2,” European Journal Of Pharmacology 949 (2023): 19.

[131] N. Shen, T. F. Wang, Q. Gan, et al., “Plant Flavonoids: Classification, Distribution, Biosynthesis, and Antioxidant Activity,” Food Chemistry 383 (2022): 13.

[132] J. W. Kim, A. R. Amin, and D. M. Shin, “Chemoprevention of Head and Neck Cancer With Green Tea Polyphenols,” Cancer Prev Res (Philadelphia, Pa) 3, no. 8 (2010): 900–909.

[133] S. Venturelli, M. Burkard, M. Biendl, et al., “Prenylated Chalcones and Flavonoids for the Prevention and Treatment of Cancer,” Nutrition (Burbank, Los Angeles County, Calif) 32, no. 11-12 (2016): 1171–1178.

[134] G. D. Kim, “Kaempferol Inhibits Angiogenesis by Suppressing HIF-1α and VEGFR2 Activation via ERK/p38 MAPK and PI3K/Akt/mTOR Signaling Pathways in Endothelial Cells,” Prev Nutr Food Sci 22, no. 4 (2017): 320–326.

[135] J. Chen, A. Y. Chen, H. Huang, et al., “The Flavonoid Nobiletin Inhibits Tumor Growth and Angiogenesis of Ovarian Cancers via the Akt Pathway,” International Journal Of Oncology 46, no. 6 (2015): 2629–2638.

[136] X. Li, Z. S. Zhang, X. H. Zhang, et al., “Cyanidin Inhibits EMT Induced by Oxaliplatin via Targeting the PDK1-PI3K/Akt Signaling Pathway,” Food Funct 10, no. 2 (2019): 592–601.

[137] Y. Chen, S. Wang, B. Geng, and Z. Yi, “Pelargonidin Induces Antitumor Effects in human Osteosarcoma Cells via Autophagy Induction, Loss of Mitochondrial Membrane Potential, G2/M Cell Cycle Arrest and Downregulation of PI3K/AKT Signalling Pathway,” J buon 23, no. 3 (2018): 735–740.

[138] C. Martinez-Perez, C. Ward, G. Cook, et al., “Novel Flavonoids as Anti-cancer Agents: Mechanisms of Action and Promise for Their Potential Application in Breast Cancer,” Biochemical Society Transactions 42, no. 4 (2014): 1017–1023.

[139] H. W. Wu, H. Huang, and Y. M. Zhao, “Interplay Between Metabolic Reprogramming and Post-translational Modifications: From Glycolysis to Lactylation,” Frontiers In Immunology 14 (2023): 12.

[140] S. Daneshvar, M. Y. Zamanian, M. S. Ivraghi, et al., “A Comprehensive View on the Apigenin Impact on Colorectal Cancer: Focusing on Cellular and Molecular Mechanisms,” Food Sci Nutr 11, no. 11 (2023): 6789–6801.

[141] J. H. Han, M. Kim, H. J. Kim, et al., “Targeting Lactate Dehydrogenase A With Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil,” International Journal Of Molecular Sciences 22, no. 10 (2021): 5406.

[142] H. S. Kim, T. Wannatung, S. Lee, et al., “Quercetin Enhances Hypoxia-mediated Apoptosis via Direct Inhibition of AMPK Activity in HCT116 Colon Cancer,” Apoptosis 17, no. 9 (2012): 938–949.

[143] J. W. Gu, K. L. Makey, K. B. Tucker, et al., “EGCG, a Major Green Tea Catechin Suppresses Breast Tumor Angiogenesis and Growth via Inhibiting the Activation of HIF-1α and NFκB, and VEGF Expression,” Vasc Cell 5, no. 1 (2013): 9.

[144] J. Y. Yao, S. Xu, Y. N. Sun, et al., “Novel CDK9 Inhibitor Oroxylin A Promotes Wild-type P53 Stability and Prevents Hepatocellular Carcinoma Progression by Disrupting both MDM2 and SIRT1 Signaling,” Acta Pharmacologica Sinica 43, no. 4 (2022): 1033–1045.

[145] H. Cheng, M. Wang, J. J. Su, et al., “Lipid Metabolism and Cancer,” Life-Basel 12, no. 6 (2022): 34.

[146] R. M. Rifaat, M. W. Kamel, M. Sharaky, Y. M. Attia, and S. A. Shouman, “Targeting Lipid Metabolism to Overcome Tamoxifen Resistance in Breast Cancer: Evaluating the Synergistic Therapeutic Potential of Quercetin,” Cancer Treat Res Commun 44 (2025): 100953.

[147] S. Gómez-Zorita, A. Lasa, N. Abendaño, et al., “Phenolic Compounds Apigenin, Hesperidin and Kaempferol Reduce in Vitro Lipid Accumulation in human Adipocytes,” Journal Of Translational Medicine 15, no. 1 (2017): 237.

[148] D. T. Coleman, R. Bigelow, and J. A. Cardelli, “Inhibition of Fatty Acid Synthase by Luteolin Post-transcriptionally Down-regulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation,” Molecular Cancer Therapeutics 8, no. 1 (2009): 214–224.

[149] K. Yang, G. Zhu, T. Peng, Y. Cheng, and X. Guo, “FASN Regulates CSE-induced Apoptosis, Oxidative Stress and Mitochondrial Damage in Type 2 Alveolar Epithelial Cells by Regulating NRF2 Expression and Nuclear Translocation,” Redox Report: Communications In Free Radical Research 30, no. 1 (2025): 2550412.

[150] Z. M. Zhang, X. Y. Yang, J. H. Yuan, Z. Y. Sun, and Y. Q. Li, “Modulation of NRF2 and UGT1A Expression by Epigallocatechin-3-gallate in Colon Cancer Cells and BALB/c Mice,” Chinese Medical Journal 122, no. 14 (2009): 1660–1665.

[151] N. S. Yarla, A. Bishayee, G. Sethi, et al., “Targeting Arachidonic Acid Pathway by Natural Products for Cancer Prevention and Therapy,” Seminars n Cancer Biology (2016): 48–81. 40-41.

[152] C. Monmai and S. H. Baek, “Anti-Inflammatory Effects of the Combined Treatment of Resveratrol- and Protopanaxadiol-Enriched Rice Seed Extract on Lipopolysaccharide-Stimulated RAW264.7 Cells,” Molecules (Basel, Switzerland) 29, no. 18 (2024).

[153] S. Pisonero-Vaquero, Á. Martínez-Ferreras, M. V. García-Mediavilla, et al., “Quercetin Ameliorates Dysregulation of Lipid Metabolism Genes via the PI3K/AKT Pathway in a Diet-induced Mouse Model of Nonalcoholic Fatty Liver Disease,” Molecular Nutrition & Food Research 59, no. 5 (2015): 879–893.

[154] S. Nimmagadda, K. Glunde, M. G. Pomper, and Z. M. Bhujwalla, “Pharmacodynamic Markers for Choline Kinase Down-regulation in Breast Cancer Cells,” Neoplasia 11, no. 5 (2009): 477–484.

[155] D. Nan, W. P. Yao, L. L. Huang, et al., “Glutamine and Cancer: Metabolism, Immune Microenvironment, and Therapeutic Targets,” Cell Communication And Signaling 23, no. 1 (2025): 17.

[156] Z. Wei, S. Ye, H. Feng, et al., “Silybin Suppresses Ovarian Cancer Cell Proliferation by Inhibiting Isocitrate Dehydrogenase 1 Activity,” Cancer Science 113, no. 9 (2022): 3032–3043.

[157] J. Li, D. Zhang, S. Wang, et al., “Baicalein Induces Apoptosis by Inhibiting the Glutamine-mTOR Metabolic Pathway in Lung Cancer,” Journal Of Advanced Research 68 (2025): 341–357.

[158] K. Wang, W. Zhang, Z. Wang, et al., “Flavokawain A Inhibits Prostate Cancer Cells by Inducing Cell Cycle Arrest and Cell Apoptosis and Regulating the Glutamine Metabolism Pathway,” Journal Of Pharmaceutical And Biomedical Analysis 186 (2020): 113288.

[159] L. Zhexian, G. Xingqi, D. Xinxin, et al., “Clinical Application Prospects of Traditional Chinese Medicine as Adjuvant Therapy for Metabolic Reprogramming in Colorectal Cancer,” Frontiers In Immunology 16 (2025): 1630279.

[160] H. Y. Wu, L. L. Pan, C. X. Gao, et al., “Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway,” Molecules (Basel, Switzerland) 24, no. 10 (2019): 11.

[161] L. J. Jia, S. Huang, X. R. Yin, et al., “Quercetin Suppresses the Mobility of Breast Cancer by Suppressing Glycolysis Through Akt-mTOR Pathway Mediated Autophagy Induction,” Life Sciences 208 (2018): 123–130.

[162] S. H. Shan, J. Y. Shi, P. Yang, et al., “Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis,” Journal Of Agricultural And Food Chemistry 65, no. 37 (2017): 8136–8144.

[163] J. Yuan, G. Peng, G. L. Xiao, et al., “Xanthohumol Suppresses Glioblastoma via Modulation of Hexokinase 2-mediated Glycolysis,” Journal Of Cancer 11, no. 14 (2020): 4047–4058.

[164] X. K. Zheng, Y. Y. Ke, A. Z. Feng, et al., “The Mechanism by Which Amentoflavone Improves Insulin Resistance in HepG2 Cells,” Molecules (Basel, Switzerland) 21, no. 5 (2016): 13.

[165] Z. Tai, Y. Lin, Y. He, et al., “Luteolin Sensitizes the Antiproliferative Effect of Interferon α/β by Activation of Janus Kinase/Signal Transducer and Activator of Transcription Pathway Signaling Through Protein Kinase A-mediated Inhibition of Protein Tyrosine Phosphatase SHP-2 in Cancer Cells,” Cell Signalling 26, no. 3 (2014): 619–628.

[166] D. Venkatesh, S. Sarkar, T. Kandasamy, and S. S. Ghosh, “In-silico Identification and Validation of Silibinin as a Dual Inhibitor for ENO1 and GLUT4 to Curtail EMT Signaling and TNBC Progression,” Computational Biology And Chemistry 115 (2025): 108312.

[167] M. Ashrafizadeh, M. R. Bakhoda, Z. Bahmanpour, et al., “Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms with Emphasis on Pancreatic Cancer,” Front Chem 8 (2020): 829.

[168] J. Wei, G. Lei, Q. Chen, et al., “Casticin Inhibits Proliferation of Non-small Cell Lung Cancer Cells Through Regulating Reprogramming of Glucose Metabolism,” Phytomedicine 136 (2025): 156278.

[169] L. Wang, M. Liu, F. Yin, et al., “Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells,” Molecules (Basel, Switzerland) 24, no. 18 (2019): 3390.

[170] Y. Li, D. Kong, A. Ahmad, et al., “Epigenetic Deregulation of miR-29a and miR-1256 by Isoflavone Contributes to the Inhibition of Prostate Cancer Cell Growth and Invasion,” Epigenetics 7, no. 8 (2012): 940–949.

[171] Z. Wang, D. Wang, S. Han, et al., “Bioactivity-guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus Suberectus on Breast Cancer,” PLoS ONE 8, no. 2 (2013): e56631.

[172] J. D. Fu, J. J. Yao, H. Wang, et al., “Effects of EGCG on Proliferation and Apoptosis of Gastric Cancer SGC7901 Cells via Down-regulation of HIF-1α and VEGF Under a Hypoxic state,” European Review For Medical And Pharmacological Sciences 23, no. 1 (2019): 155–161.

[173] F. Chen, M. Zhuang, C. Zhong, et al., “Baicalein Reverses Hypoxia-induced 5-FU Resistance in Gastric Cancer AGS Cells Through Suppression of Glycolysis and the PTEN/Akt/HIF-1α Signaling Pathway,” Oncology Reports 33, no. 1 (2015): 457–463.

[174] Q. Liu, X. Chen, Y. Tan, et al., “Natural Products as Glycolytic Inhibitors for Cervical Cancer Treatment: A Comprehensive Review,” Biomedicine & Pharmacotherapy 175 (2024): 116708.

[175] D. Jia, C. Liu, Z. Zhu, et al., “Novel Transketolase Inhibitor Oroxylin A Suppresses the Non-oxidative Pentose Phosphate Pathway and Hepatocellular Carcinoma Tumour Growth in Mice and Patient-derived Organoids,” Clinical And Translational Medicine 12, no. 11 (2022): e1095.

[176] K. Toshida, S. Itoh, N. Iseda, et al., “The Impact of TP53-Induced Glycolysis and Apoptosis Regulator on Prognosis in Hepatocellular Carcinoma: Association With Tumor Microenvironment and Ferroptosis,” Liver Cancer 14, no. 1 (2025): 36–57.

[177] P. Giridharan, S. T. Somasundaram, K. Perumal, et al., “Novel Substituted Methylenedioxy Lignan Suppresses Proliferation of Cancer Cells by Inhibiting Telomerase and Activation of c-myc and Caspases Leading to Apoptosis,” British Journal Of Cancer 87, no. 1 (2002): 98–105.

[178] M. Alam, S. Ali, G. M. Ashraf, et al., “Epigallocatechin 3-gallate: From Green Tea to Cancer Therapeutics,” Food Chemistry 379 (2022): 132135.

[179] Y. Zhou, L. Chen, D. Ding, et al., “Cyanidin-3-O-glucoside Inhibits the β-catenin/MGMT Pathway by Upregulating miR-214-5p to Reverse Chemotherapy Resistance in Glioma Cells,” Scientific Reports 12, no. 1 (2022): 7773.

[180] J. Cao, X. Ma, X. Yan, et al., “Kaempferol Induces Mitochondrial Dysfunction and Mitophagy by Activating the LKB1/AMPK/MFF Pathway in Breast Precancerous Lesions,” Phytotherapy Research 37, no. 8 (2023): 3602–3616.

[181] A. Guo, Y. Chang, J. Lin, et al., “Resveratrol Enhances Anticancer Effects of Silybin on HepG2 Cells and H22 Tumor-bearing Mice via Inducing G2/M Phase Arrest and Increasing Bax/Bcl-2 Ratio,” Combinatorial Chemistry & High Throughput Screening 28, no. 1 (2025): 89–98.

[182] T. Puig, A. Vázquez-Martín, J. Relat, et al., “Fatty Acid Metabolism in Breast Cancer Cells: Differential Inhibitory Effects of Epigallocatechin Gallate (EGCG) and C75,” Breast Cancer Research And Treatment 109, no. 3 (2008): 471–479.

[183] K. Y. Jang, S. J. Jeong, S. H. Kim, et al., “Activation of Reactive Oxygen Species/AMP Activated Protein Kinase Signaling Mediates Fisetin-induced Apoptosis in Multiple Myeloma U266 Cells,” Cancer Letters 319, no. 2 (2012): 197–202.

[184] D. Hess and R. A. Igal, “Genistein Downregulates De Novo Lipid Synthesis and Impairs Cell Proliferation in human Lung Cancer Cells,” Experimental Biology And Medicine (Maywood, NJ) 236, no. 6 (2011): 707–713.

[185] J. Li, T. Wang, P. Liu, et al., “Hesperetin Ameliorates Hepatic Oxidative Stress and Inflammation via the PI3K/AKT-Nrf2-ARE Pathway in Oleic Acid-induced HepG2 Cells and a Rat Model of High-fat Diet-induced NAFLD,” Food Funct 12, no. 9 (2021): 3898–3918.

[186] N. M. Borradaile, L. E. de Dreu, P. H. Barrett, and M. W. Huff, “Inhibition of Hepatocyte apoB Secretion by Naringenin: Enhanced Rapid Intracellular Degradation Independent of Reduced Microsomal Cholesteryl Esters,” Journal Of Lipid Research 43, no. 9 (2002): 1544–1554.

[187] W. Jäger, A. Gruber, B. Giessrigl, et al., “Metabolomic Analysis of Resveratrol-induced Effects in the human Breast Cancer Cell Lines MCF-7 and MDA-MB-231,” Omics 15, no. 1-2 (2011): 9–14.

[188] X. Y. Wang, L. Dai, Y. Liu, and G. Li, “Untargeted Metabolomic Analysis of the Therapeutic Effects of Pholiota Adiposa in H22 Hepatocellular Carcinoma Tumor-bearing Mice,” Journal Of Bioenergetics And Biomembranes 57, no. 4-5 (2025): 315–335.

[189] F. Z. Mokhfi, M. Al Amin, M. Zehravi, et al., “Alkaloid-based Modulators of the PI3K/Akt/mTOR Pathway for Cancer Therapy: Understandings From Pharmacological Point of View,” Chemico-Biological Interactions 402 (2024): 15.

[190] W. Zhou, A. Asif, C. Situ, J. Wang, and H. Hao, “Multiple Target and Regulatory Pathways of berberine,” Phytomedicine 146 (2025): 157030.

[191] L. Cheng, C. R. Wu, L. H. Zhu, H. Li, and L. X. Chen, “Physapubescin, a Natural Withanolide as a Kidney-type Glutaminase (KGA) Inhibitor,” Bioorganic & Medicinal Chemistry Letters 27, no. 5 (2017): 1243–1246.

[192] W. H. Zhu, W. Zhang, and N. Xu, “Dihydroartemisinin Induces Apoptosis and Downregulates Glucose Metabolism in JF-305 Pancreatic Cancer Cells,” Rsc Advances 8, no. 37 (2018): 20692–20700.

[193] S. Fakhri, S. Z. Moradi, S. Y. Moradi, et al., “Phytochemicals Regulate Cancer Metabolism Through Modulation of the AMPK/PGC-1α Signaling Pathway,” BMC cancer 24, no. 1 (2024): 29.

[194] R. Yang, X. L. Fang, Q. Zhen, Q. Y. Chen, and C. J. Feng, “Mitochondrial Targeting Nano-curcumin for Attenuation on PKM2 and FASN,” Colloids And Surfaces B-Biointerfaces 182 (2019): 7.

[195] S. W. Kim, M. J. Cha, S. K. Lee, et al., “Curcumin Treatment in Combination With Glucose Restriction Inhibits Intracellular Alkalinization and Tumor Growth in Hepatoma Cells,” International Journal Of Molecular Sciences 20, no. 10 (2019): 17.

[196] R. Wei, L. M. Mao, P. Xu, et al., “Suppressing Glucose Metabolism With Epigallocatechin-3-gallate (EGCG) Reduces Breast Cancer Cell Growth in Preclinical Models,” Food & Function 9, no. 11 (2018): 5682–5696.

[197] M. Puxeddu, R. Silvestri, and G. L. Regina, “Metabolism, a Blossoming Target for Small-Molecule Anticancer Drugs,” Molecules (Basel, Switzerland) 30, no. 17 (2025): 39.

[198] D. Uogintaite, R. Baniene, A. Jasukaitiene, et al., “Effect of Fireweed (Chamerion angustifolium L.) Extracts and Oenothein B on Colon Cancer Cells: Impact of Leaf Fermentation on Viability and Mitochondrial Function,” Medicina (Kaunas, Lithuania) 61, no. 11 (2025): 1957.

[199] A. Chauhan, S. Dewali, V. M. Pathak, et al., “Therapeutic Role of Allicin in Gastrointestinal Cancers: Mechanisms and Safety Aspects,” Discov Oncol 16, no. 1 (2025): 1731.

[200] I. Debnath and M. Kundu, “Therapeutic Potential of Natural Compounds in Targeting Cancer Stem Cells: A Promising Approach for Cancer Treatment,” Discov Oncol 16, no. 1 (2025): 1433.

[201] E. M. Kamel, D. A. Abdelrheem, S. I. Othman, S. Maodaa, and A. M. Lamsabhi, “A Multifaceted Mechanistic Approach to Assess the Inhibitory Potential of Broccoli-Derived Glucosinolates against Tumor-Associated Carbonic Anhydrase IX,” Arch Pharm (Weinheim) 358, no. 6 (2025): e70019.

[202] K. Iwar, K. Ochar, Y. A. Seo, B. K. Ha, and S. H. Kim, “Alliums as Potential Antioxidants and Anticancer Agents,” International Journal Of Molecular Sciences 25, no. 15 (2024): 8079.

[203] D. Lu, L. Yuan, G. Chen, et al., “Exploring the Effect of Huangqi Fuling Decoction on Gastric Cancer Based on UPLC-MS, Network Pharmacology and Experiments in Vitro,” BMC Complement Med Ther 25, no. 1 (2025): 405.

[204] B. Arneth, “Tumor Microenvironment,” Medicina-Lithuania 56, no. 1 (2020): 21.

[205] J. J. Wang, K. F. Lei, and F. Han, “Tumor Microenvironment: Recent Advances in Various Cancer Treatments,” European Review For Medical And Pharmacological Sciences 22, no. 12 (2018): 3855–3864.

[206] W. L. Zhang, S. B. Li, C. T. Li, T. Y. Li, and Y. Y. Huang, “Remodeling Tumor Microenvironment With Natural Products to Overcome Drug Resistance,” Frontiers In Immunology 13 (2022): 22.

[207] R. A. Glabman, P. L. Choyke, and N. Sato, “Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy,” Cancers 14, no. 16 (2022): 21.

[208] C. Li, X. Wang, L. Xing, et al., “Huaier-induced Suppression of Cancer-associated Fibroblasts Confers Immunotherapeutic Sensitivity in Triple-negative Breast Cancer,” Phytomedicine 135 (2024): 156051.

[209] P. Dauer, X. Zhao, V. K. Gupta, et al., “Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression,” Cancer Research 78, no. 5 (2018): 1321–1333.

[210] C. Guirong, H. Lili, D. Guifang, et al., “Qingre Huayu Jianpi Decoction Suppresses Colorectal Tumorigenesis by Inhibiting Cancer Stem Cells and Cancer-associated Fibroblasts,” Journal Of Ethnopharmacology 347 (2025): 119722.

[211] X. H. Yao and Y. Zeng, “Tumour Associated Endothelial Cells: Origin, Characteristics and Role in Metastasis and Anti-angiogenic Resistance,” Frontiers In Physiology 14 (2023): 8.

[212] Z. P. Fu, X. Chen, S. W. Guan, et al., “Curcumin Inhibits Angiogenesis and Improves Defective Hematopoiesis Induced by Tumor-derived VEGF in Tumor Model Through Modulating VEGF-VEGFR2 Signaling Pathway,” Oncotarget 6, no. 23 (2015): 19469–19482.

[213] Q. Zhang, J. Liu, H. Duan, et al., “Activation of Nrf2/HO-1 Signaling: An Important Molecular Mechanism of Herbal Medicine in the Treatment of Atherosclerosis via the Protection of Vascular Endothelial Cells From Oxidative Stress,” Journal Of Advanced Research 34 (2021): 43–63.

[214] Y. R. Wang, B. Wang, M. Guerram, et al., “Deoxypodophyllotoxin Suppresses Tumor Vasculature in HUVECs by Promoting Cytoskeleton Remodeling Through LKB1-AMPK Dependent Rho A Activation,” Oncotarget 6, no. 30 (2015): 29497–29512.

[215] Z. Li, M. Huang, J. Wang, et al., “Betulin, an Active Component From Chinese Herb Birch Bark, Suppresses Tumor Angiogenesis and Tumor Growth by Inhibiting the PAX2/VEGF-A/VEGR2 Signaling Pathway in Non-small Cell Lung Cancer,” Phytomedicine 148 (2025): 157445.

[216] J. S. Di Martino, T. Akhter, and J. J. Bravo-Cordero, “Remodeling the ECM: Implications for Metastasis and Tumor Dormancy,” Cancers 13, no. 19 (2021): 12.

[217] C. Lou, Z. Zhu, Y. Zhao, R. Zhu, and H. Zhao, “Arctigenin, a Lignan From Arctium Lappa L., Inhibits Metastasis of human Breast Cancer Cells Through the Downregulation of MMP-2/-9 and Heparanase in MDA-MB-231 Cells,” Oncology Reports 37, no. 1 (2017): 179–184.

[218] H. Y. Du, M. Olivo, R. Mahendran, et al., “Hypericin Photoactivation Triggers Down-regulation of Matrix Metalloproteinase-9 Expression in Well-differentiated human Nasopharyngeal Cancer Cells,” Cellular And Molecular Life Sciences 64, no. 7-8 (2007): 979–988.

[219] P. Song, F. Song, T. T. Shao, et al., “Natural Products: Promising Therapeutics for Targeting Regulatory Immune Cells in the Tumor Microenvironment,” Frontiers In Pharmacology 15 (2024): 23.

[220] Z. C. Dongye, X. P. Wu, Y. X. Wen, et al., “Icaritin and Intratumoral Injection of CpG Treatment Synergistically Promote T Cell Infiltration and Antitumor Immune Response in Mice,” International Immunopharmacology 111 (2022): 12.

[221] S. M. Qiao, C. J. Lv, Y. Tao, et al., “Arctigenin Disrupts NLRP3 Inflammasome Assembly in Colonic Macrophages via Downregulating Fatty Acid Oxidation to Prevent Colitis-associated Cancer,” Cancer Letters 491 (2020): 162–179.

[222] R. Yao, Y. Zhang, W. Yu, et al., “Jianpi-huayu Decotion Regulates TREM1/DAP12 Pathway to Improve the Immunosuppressive Tumor Microenvironment and Enhance the Anti-hepatocellular Carcinoma Effect of PD-1 Inhibitors,” Journal Of Ethnopharmacology 356 (2026): 120846.

[223] H. Zhi, H. Fu, Y. Zhang, et al., “Progress of cGAS-STING Signaling Pathway-based Modulation of Immune Response by Traditional Chinese Medicine in Clinical Diseases,” Frontiers In Immunology 15 (2024): 1510628.

[224] J. L. Huo, W. J. Fu, Z. H. Liu, et al., “Research Advance of Natural Products in Tumor Immunotherapy,” Frontiers In Immunology 13 (2022): 9.

[225] H. Gao, N. Kang, C. Hu, et al., “Ginsenoside Rb1 Exerts Anti-inflammatory Effects in Vitro and in Vivo by Modulating Toll-Like Receptor 4 Dimerization and NF-kB/MAPKs Signaling Pathways,” Phytomedicine 69 (2020): 153197.

[226] T. Hayashi, K. Fujita, M. Matsushita, and N. Nonomura, “Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer,” Cancers (Basel) 11, no. 8 (2019): 1153.

[227] Z. Su, Y. Li, Z. Zhou, et al., “Herbal Medicine for Colorectal Cancer Treatment: Molecular Mechanisms and Clinical Applications,” Cell Proliferation 58, no. 10 (2025): e70065.

[228] X. Nie, L. Fu, Y. F. Cheng, et al., “Garcinone E Suppresses Breast Cancer Growth and Metastasis by Modulating Tumor-associated Macrophages Polarization via STAT6 Signaling,” Phytotherapy Research 37, no. 10 (2023): 4442–4456.

[229] X. X. Deng, Y. N. Jiao, H. F. Hao, et al., “Taraxacum Mongolicum Extract Inhibited Malignant Phenotype of Triple-negative Breast Cancer Cells in Tumor-associated Macrophages Microenvironment Through Suppressing IL-10 /STAT3 / PD-L1 Signaling Pathways,” Journal f Ethnopharmacology 274 (2021): 113978.

[230] J. Xie, X. Du, Y. Li, et al., “Berberine Shaping the Tumor Immune Landscape via Pyroptosis,” Cellular Immunology 408 (2025): 104908.

[231] L. Li, M. Zhang, T. Liu, et al., “Quercetin-ferrum Nanoparticles Enhance Photothermal Therapy by Modulating the Tumor Immunosuppressive Microenvironment,” Acta Biomaterialia 154 (2022): 454–466.

[232] W. Hu, Y. Ma, Q. Zhang, et al., “DCs-targeted Full-cell Nanovaccine Based on Chitosan Oligosaccharide Self-assembled With Ganoderma Lucidum Polysaccharide for Enhancing Tumor Immunotherapy,” International Journal Of Biological Macromolecules 334, no. Pt 1 (2025): 148934.

[233] Y. B. Feng, L. Chen, F. X. Chen, et al., “Immunopotentiation Effects of Apigenin on NK Cell Proliferation and Killing Pancreatic Cancer Cells,” International Journal Of Immunopathology And Pharmacology 37 (2023): 3946320231161174.

[234] J. Gnanagurusamy, R. Sabanayagam, S. Krishnamoorthy, V. Balasubramanian, and S. Muthusami, “EGCG Remodels the TGF-β Cervical Cancer Micro-environment towards Immune Responsiveness,” Cellular Immunology 418 (2025): 105027.

[235] C. J. Wang, C. Wang, J. Han, et al., “Effect of Combined Treatment With Recombinant Interleukin-2 and Allicin on Pancreatic Cancer,” Molecular Biology Reports 40, no. 12 (2013): 6579–6585.

[236] L. O. Afolabi, J. C. Bi, L. Chen, and X. C. Wan, “A Natural Product, Piperlongumine (PL), Increases Tumor Cells Sensitivity to NK Cell Killing,” International Immunopharmacology 96 (2021): 15.

[237] B. L. Wang, H. Su, Y. Chen, J. Wang, and G. L. Xu, “A Role for Trichosanthin in the Expansion of CD4CD25 Regulatory T Cells,” Scandinavian Journal f Immunology 71, no. 4 (2010): 258–266.

[238] H. Zhou, Y. Zhuang, Y. Liang, et al., “Curcumin Exerts Anti-tumor Activity in Colorectal Cancer via Gut Microbiota-mediated CD8(+) T Cell Tumor Infiltration and Ferroptosis,” Food Funct 16, no. 9 (2025): 3671–3693.

[239] W. Liu, H. Zhou, W. Lai, et al., “Artesunate Induces Melanoma Cell Ferroptosis and Augments Antitumor Immunity Through Targeting Ido1,” Cell Communication and Signaling 22, no. 1 (2024): 378.

[240] C. J. Bao, M. Q. Liu, Y. N. Liu, et al., “A Structurally Distinct Arabinose-bridged Arabinogalactan From Lycium barbarum as a TLR4-activating Adjuvant for Nanovaccine-based Cancer Immunotherapy,” Carbohydrate Polymers 373 (2026): 124618.

[241] S. Siddiqui and R. Glauben, “Fatty Acid Metabolism in Myeloid-Derived Suppressor Cells and Tumor-Associated Macrophages: Key Factor in Cancer Immune Evasion,” Cancers (Basel) 14, no. 1 (2022): 250.

[242] Y. C. Huang, S. J. Huang, H. Y. Yang, et al., “Development of a Compound Herbal Formulation (HBK) With Antitumor and Antioxidant Functions for Cancer Adjuvant Therapy,” Phytomedicine 147 (2025): 157212.

[243] G. X. Wei, Y. H. Xu, T. Peng, et al., “Sanguinarine Exhibits Antitumor Activity via Up-regulation of Fas-associated Factor 1 in Non-small Cell Lung Cancer,” Journal Of Biochemical And Molecular Toxicology 31, no. 8 (2017): 8.

[244] M. J. Saadh, M. A. Mustafa, H. Malathi, et al., “Targeting the Pancreatic Tumor Microenvironment by Plant-derived Products and Their Nanoformulations,” Medical Oncology 41, no. 8 (2024): 201.

[245] M. H. Akhter, S. Kumar, and S. Nomani, “Sonication Tailored Enhance Cytotoxicity of Naringenin Nanoparticle in Pancreatic Cancer: Design, Optimization, and in Vitro Studies,” Drug Development And Industrial Pharmacy 46, no. 4 (2020): 659–672.

[246] B. Q. Li, H. L. Shao, L. Gao, et al., “Nano-drug co-delivery System of Natural Active Ingredients and Chemotherapy Drugs for Cancer Treatment: A Review,” Drug Delivery 29, no. 1 (2022): 2130–2161.

[247] S. Hashem, T. A. Ali, S. Akhtar, et al., “Targeting Cancer Signaling Pathways by Natural Products: Exploring Promising Anti-cancer Agents,” Biomedicine & Pharmacotherapy 150 (2022): 12.

[248] H. P. Zhang and Y. S. Li, “Targeting the Breast Tumor Microenvironment by Plant-derived Products and Their Nanoformulations,” Journal Of Drug Delivery Science And Technology 93 (2024): 20.

[249] H. M. Alharbi, T. Alqahtani, A. H. Alamri, et al., “Nanotechnological Synergy of Mangiferin and Curcumin in Modulating PI3K/Akt/mTOR Pathway: A Novel front in Ovarian Cancer Precision Therapeutics,” Frontiers In pharmacology 14 (2023): 1276209.

[250] M. Mihaila, N. Badea, M. Birliga, et al., “Ginkgo Biloba and Green Tea Polyphenols Captured Into Collagen-Lipid Nanocarriers: A Promising Synergistically Approach for Apoptosis Activation and Tumoral Cell Cycle Arrest,” International Journal Of Molecular Sciences 26, no. 19 (2025): 26.

[251] R. G. Kalinova, I. V. Dimitrov, Y. Ilieva, et al., “Antineoplastic Activity of Podophyllotoxin and Juniper Extracts Encapsulated in MPEG-b-PLA Diblock Copolymer Micelles in Cutaneous Squamous Carcinoma Cells,” International Journal of Molecular Sciences 26, no. 11 (2025): 5167.

[252] W. Li, Y. Fu, S. Yan, et al., “Construction and Evaluation of pH-sensitive Nanoparticles With Resveratrol Release to Trigger the Immunogenic Cell Death in Colon Cancer Cellsin Vitro,” Colloids And Surfaces B, Biointerfaces 255 (2025): 114895.

[253] X. Zhou, P. Zhang, N. Liu, et al., “Enhancing Chemotherapy for Pancreatic Cancer Through Efficient and Sustained Tumor Microenvironment Remodeling With a Fibroblast-targeted Nanosystem,” J Control Release 361 (2023): 161–177.

[254] M. Dey, M. Das, A. Chowhan, and T. K. Uri, “Breaking the Barricade of Oral Chemotherapy Through Polysaccharide Nanocarrier,” International Journal Of Biological Macromolecules 130 (2019): 34–49.

[255] N. Wang, J. Hu, L. Jin, et al., “Inulin and Hyaluronic Acid-based Oral Liposome for Enhanced Photo-chemotherapy Against Orthotopic Colon Cancer and Its Reversal Effects on Tumor Hypoxia and Intestinal Microbiota,” International Journal Of Biological Macromolecules 304, no. Pt 2 (2025): 140996.

[256] X. Y. Liu, X. Z. Teng, J. H. Wang, et al., “Exosome-based Mucosal Therapeutic and Diagnostic System: Towards Clinical Translation,” Journal Of Controlled Release 385 (2025): 24.

[257] S. R. Mallery, G. D. Stoner, P. E. Larsen, et al., “Formulation and in-vitro and in-vivo Evaluation of a Mucoadhesive Gel Containing Freeze Dried Black Raspberries: Implications for Oral Cancer Chemoprevention,” Pharmaceutical Research 24, no. 4 (2007): 728–737.

[258] B. Shen, Y. Zhu, F. Wang, et al., “Fabrication and in Vitro/Vivo Evaluation of Quercetin Nanocrystals Stabilized by Glycyrrhizic Acid for Liver Targeted Drug Delivery,” Int J Pharm X 7 (2024): 100246.

[259] Y. Li, L. Liu, H. Shang, et al., “Self-Assembling Anchorage of Hyaluronic Acid on the Nanoparticle Surface Confers Superiority of Triple Negative Breast Cancer Treatment,” Pharmaceutics 14, no. 11 (2022): 2461.

[260] D. Huang, Z. Tang, X. Pu, et al., “A Novel Cabazitaxel Liposomes Modified With Ginsenoside Rk1 for Cancer Targeted Therapy,” Acupuncture And Herbal Medicine 4, no. 1 (2024): 113–121.

[261] X. Han, G. Zhang, X. Wu, et al., “Microfluidics-enabled Fluorinated Assembly of EGCG-ligands-siTOX Nanoparticles for Synergetic Tumor Cells and Exhausted T Cells Regulation in Cancer Immunotherapy,” J Nanobiotechnology 22, no. 1 (2024): 90.

[262] Y. Zhao, Y. Bai, M. Li, et al., “A pH-triggered N-oxide Polyzwitterionic Nano-drug Loaded System for the Anti-tumor Immunity Activation Research,” J Nanobiotechnology 22, no. 1 (2024): 420.

[263] L. Raimondi, A. De Luca, G. Giavaresi, et al., “Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation,” Current Medicinal Chemistry 27, no. 2 (2020): 187–215.

[264] S. Uramova, P. Kubatka, Z. Dankova, et al., “Plant Natural Modulators in Breast Cancer Prevention: Status Quo and Future Perspectives Reinforced by Predictive, Preventive, and Personalized Medical Approach,” Epma Journal 9, no. 4 (2018): 403–419.

[265] Y. A. Salama, A. El-Karef, A. M. El Gayyar, and N. Abdel-Rahman, “Beyond Its Antioxidant Properties: Quercetin Targets Multiple Signalling Pathways in Hepatocellular Carcinoma in Rats,” Life Sciences 236 (2019): 116933.

[266] G. F. He, T. L. Mu, Y. L. Yuan, et al., “Effects of Notch Signaling Pathway in Cervical Cancer by Curcumin Mediated Photodynamic Therapy and Its Possible Mechanisms in Vitro and in Vivo,” Journal Of Cancer 10, no. 17 (2019): 4114–4122.

[267] F. E. Cheng, X. Zhang, X. Zou, et al., “The Role and Mechanism of Artemisia Annua L. in Cancer Treatment,” Journal Of Ethnopharmacology 353 (2025): 120447. Pt B.

[268] S. Xiao, H. Jia, Y. Guo, X. Ding, and A. Zheng, “Chemoprophylactic Effects of Epigallocatechin Gallate in Female Reproductive Cancers—A Review,” J Diet Suppl 22, no. 4 (2025): 487–510.

[269] Z. W. Yao and H. Zhu, “Pharmacological Mechanisms and Drug Delivery Systems of Ginsenoside Rg3: A Comprehensive Review,” Pharmacological Research 216 (2025): 107799.

[270] H. Y. Tan, N. Wang, K. Man, et al., “Autophagy-induced RelB/p52 Activation Mediates Tumour-associated Macrophage Repolarisation and Suppression of Hepatocellular Carcinoma by Natural Compound baicalin,” Cell Death & Disease 6 (2015): 13.

[271] Y. Chen, Z. Wang, C. Zhang, et al., “Revealing the Mechanism of Natural Product-induced Immunogenic Cell Death: Opening a New Chapter in Tumor Immunotherapy,” Frontiers In Immunology 15 (2024): 1470071.

[272] K. W. Tan, Y. Li, J. W. Paxton, N. P. Birch, and A. Scheepens, “Identification of Novel Dietary Phytochemicals Inhibiting the Efflux Transporter Breast Cancer Resistance Protein (BCRP/ABCG2),” Food Chemistry 138, no. 4 (2013): 2267–2274.

[273] L. Liang, J. Wu, J. Luo, et al., “Oxymatrine Reverses 5-fluorouracil Resistance by Inhibition of Colon Cancer Cell Epithelial-mesenchymal Transition and NF-κB Signaling in Vitro,” Oncology Letters 19, no. 1 (2020): 519–526.

[274] D. Yu, H. Hu, Q. Zhang, et al., “Acevaltrate as a Novel Ferroptosis Inducer With Dual Targets of PCBP1/2 and GPX4 in Colorectal Cancer,” Signal Transduct Target Ther 10, no. 1 (2025): 211.

[275] M. J. Zhang, X. Wan, M. Shi, et al., “Curcuminoids WM03 Inhibits Ovarian Cancer Cisplatin-resistant Cells Proliferation and Reverses Cisplatin Resistance by Targeting DYRK2,” Phytomedicine 142 (2025): 156632.

[276] T. Chen, Y. Wei, S. Yin, et al., “Construction and Evaluation of BAL-PTX Co-Loaded Lipid Nanosystem for Promoting the Anti-Lung Cancer Efficacy of Paclitaxel and Reducing the Toxicity of Chemotherapeutic Drugs,” Int J Nanomedicine 19 (2024): 7775–7797.

[277] D. Delmas, F. Hermetet, and V. Aires, “PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy,” Cancers (Basel) 13, no. 18 (2021): 4509.

[278] D. Sun, Y. Zou, L. Song, et al., “A Cyclodextrin-based Nanoformulation Achieves co-delivery of Ginsenoside Rg3 and Quercetin for Chemo-immunotherapy in Colorectal Cancer,” Acta Pharm Sin B 12, no. 1 (2022): 378–393.

[279] D. C. da Silva, G. D. C. Orfali, M. G. Santana, et al., “Antitumor Effect of Isoquercetin on Tissue Vasohibin Expression and Colon Cancer Vasculature,” Oncotarget 13 (2022): 307–318.

[280] P. Goleij, M. M. Heidari, H. Motevalli, et al., “Targeting the HGF/MET Axis in Cancer: Therapeutic Promise for Natural Compounds,” European Journal Of Medicinal Chemistry 298 (2025): 118027.

[281] Z. W. Wu, X. C. Liu, C. X. Quan, et al., “Novel Galactose-rich Polysaccharide From Ganoderma lucidum: Structural Characterization and Immunomodulatory Activities,” Carbohydrate Polymers 362 (2025): 123695.

[282] H. Xiao, Y. Cao, Z. Wang, and C. Liu, “Recent Advances in Astragaloside IV Modulate Immune Response and Skin Cells Promoting Wound Healing,” Tissue Eng Part B Rev (2025).

[283] E. Abdelhakeem, H. Attia, M. M. Hashem, et al., “Innovative Antimicrobial Nanofibers: Natural Integrations for Enhanced Wound Healing and Biofilm Disruption,” Aaps Pharmscitech [Electronic Resource] 26, no. 6 (2025): 181.

[284] Y. Zhou, L. Tao, J. H. Qiu, et al., “Tumor Biomarkers for Diagnosis, Prognosis and Targeted Therapy,” Signal Transduction And Targeted Therapy 9, no. 1 (2024): 86.

[285] C. Y. Fang, C. C. Wu, H. Y. Hsu, et al., “EGCG Inhibits Proliferation, Invasiveness and Tumor Growth by Up-regulation of Adhesion Molecules, Suppression of Gelatinases Activity, and Induction of Apoptosis in Nasopharyngeal Carcinoma Cells,” International Journal Of Molecular Sciences 16, no. 2 (2015): 2530–2558.

[286] Y. Y. Zhao, L. S. C. Dunmall, Z. G. Cheng, Y. H. Wang, and L. L. Si, “Natural Products Targeting Glycolysis in Cancer,” Frontiers In Pharmacology 13 (2022): 18.

[287] M. Ke, Z. Zhang, B. Xu, et al., “Baicalein and baicalin Promote Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells,” International Immunopharmacology 75 (2019): 105824.

[288] L. Wang, X. Y. Liu, H. Z. Lv, et al., “Research Progress on Natural Products That Regulate miRNAs in the Treatment of Osteosarcoma,” Biology-Basel 14, no. 1 (2025): 26.

[289] K. El Bairi, A. G. Atanasov, M. Amrani, and S. Afqir, “The Arrival of Predictive Biomarkers for Monitoring Therapy Response to Natural Compounds in Cancer Drug Discovery,” Biomedicine & Pharmacotherapy 109 (2019): 2492–2498.

[290] C. Liu, Y. Yu, G. Wang, et al., “From Tumor Mutational Burden to Characteristic Targets Analysis: Identifying the Predictive Biomarkers and Natural Product Interventions in Cancer Management,” Frontiers In Nutrition 9 (2022): 14.

[291] M. Sharma and T. O. Tollefsbol, “Combinatorial Epigenetic Mechanisms of Sulforaphane, Genistein and Sodium Butyrate in Breast Cancer Inhibition,” Experimental Cell Research 416, no. 1 (2022): 113160.

[292] Z. Pu, F. Ge, Y. Wang, et al., “Ginsenoside-Rg3 Inhibits the Proliferation and Invasion of Hepatoma Carcinoma Cells via Regulating Long Non-coding RNA HOX Antisense Intergenic,” Bioengineered 12, no. 1 (2021): 2398–2409.

[293] Y. Zhao, L. Jing, L. Han, C. Guo, and Q. Yang, “Coumarins in the Tumor-immune Application: From Molecular Mechanisms to Therapeutic Innovations,” Frontiers In mmunology 16 (2025): 1681892.

[294] S. Y. Shen and H. F. Zhuang, “Homoharringtonine in the Treatment of Acute Myeloid Leukemia: A Review,” Medicine 103, no. 44 (2024): 9.

[295] S. You, M. J. Wang, Z. Y. Hou, et al., “ACAT1 Induces the Differentiation of Glioblastoma Cells by Rewiring Choline Metabolism,” Int J Biol Sci 20, no. 14 (2024): 5576–5593.

[296] J. L. Huang, L. M. Wu, S. Q. Wu, et al., “A Small Molecule Targets LIC1 to Suppress Lung Tumor Growth by Inducing Autophagy,” Nature Chemical Biology (2025).

[297] J. Peterson, P. Lagiou, E. Samoli, et al., “Flavonoid Intake and Breast Cancer Risk: A Case-control Study in Greece,” British Journal Of Cancer 89, no. 7 (2003): 1255–1259.

[298] J. Wu, C. Shao, Y. Dong, et al., “Qu-yu-jie-du Decoction Maintenance Therapy Improves Postoperative Survival in Metastatic Colorectal Cancer: A Single-center Randomized Trial With 36-month Follow-up,” Phytomedicine 146 (2025): 157143.

[299] Y. Yang, W. Ge, W. Luo, et al., “Effects of Chinese Herbal Medicine on the Secondary Prevention of Chemotherapy-induced Thrombocytopenia in Malignant Solid Tumors, a Randomized Clinical Trial,” Phytomedicine 144 (2025): 156871.

[300] R. Sadahiro, K. Ohbuchi, T. Nakaya, et al., “Metabolome Profiling of Yokukansan in Preventing Postoperative Delirium in Elderly Cancer Patients: A Reverse Translational Study,” Psychiatry And Clinical Neurosciences 79, no. 10 (2025): 685–696.

[301] C. Y. Wang, X. Y. Lan, J. X. Gu, et al., “Application of Functionalized Liposomes in the Delivery of Natural Products,” Progress In Biochemistry And Biophysics 51, no. 11 (2024): 2947–2959.

[302] J. J. Peng, L. Wang, M. G. Wang, et al., “Yeast Synthetic Biology for the Production of Lycium Barbarum Polysaccharides,” Molecules (Basel, Switzerland) 26, no. 6 (2021): 9.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.